Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Two years ago, Eli ... insulin market. Lilly has been under pressure in the US over its pricing for insulin products, and earlier this year launched a generic of its own Humalog brand of fast ...

More than three years after approving two biosimilars referencing Sanofi’s long ... (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

(Reuters) - Novo Nordisk (NYSE:NVO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, ...